{"id":138022,"date":"2022-11-25T09:19:03","date_gmt":"2022-11-25T14:19:03","guid":{"rendered":"https:\/\/44.250.171.167\/?p=138022"},"modified":"2022-11-25T09:19:04","modified_gmt":"2022-11-25T14:19:04","slug":"marksans-pharma-limited-q2-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/marksans-pharma-limited-q2-fy23-earnings-conference-call-insights\/","title":{"rendered":"Marksans Pharma Limited Q2 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><strong>Key highlights from Marksans Pharma Limited (<a href=\"https:\/\/44.250.171.167\/symbol\/MARKSANS\/\">MARKSANS<\/a>) Q2 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>[00:12:45] Madhav Shastri asked about the new acquisition made of Teva Pharma, and the expected capex on the facility. Mark Saldanha MD clarified that the amount the company plans to spend including the acquisition cost and capex is INR200 crore.<\/li>\n<\/ul>\n<ul>\n<li>[00:13:36] Madhav Shastri asked about the plans for the US market. Mark Saldanha MD replied that the company will have to get the plant registered in the US, but also plan to utilize infrastructure for both US and Europe.<\/li>\n<\/ul>\n<ul>\n<li>[00:18:28] Prerit Choudhary from Green Portfolio asked that once MARKSANS start making the API, if it\u2019s planned to sell it to the outside market or captive consumption. Mark Saldanha MD answered that it\u2019s only for captive consumption.<\/li>\n<\/ul>\n<ul>\n<li>[00:19:14] Prerit Choudhary from Green Portfolio asked about the use of restricted cash balance of INR18 crore. Jitendra Sharma CFO replied that the amount is into escrow account kept towards the buyback of shares, which is going on right now.<\/li>\n<\/ul>\n<ul>\n<li>[00:20:30] Nitin Agarwal with DAM Capital enquired about filing target in the US for the next couple of years. Mark Saldanha MD answered that the company is working on close to about 30 products right now and is expecting approvals every year, with 2023 seeing 5 ANDAs getting approved. And on an avg. 7-8 product approval per year.<\/li>\n<\/ul>\n<ul>\n<li>[00:21:21] Nitin Agarwal with DAM Capital also asked about the split between OTC and Rx products in the expected approvals. Mark Saldanha MD answered that probably about 65-70% will be in OTC and balance in Rx.<\/li>\n<\/ul>\n<ul>\n<li>[00:29:00] Agastya Dave from CAO Capital asked when the margins can be expected going to the 20% level for the entire portfolio for MARKSANS as a whole. Mark Saldanha MD replied that the company is doing better now at 17%. So with input cost price reduction and freight cost coming down, if the current trend continues, the 20% number can be expected next year.<\/li>\n<\/ul>\n<ul>\n<li>[00:32:28] Agastya Dave from CAO Capital asked about the backward integration project. Mark Saldanha MD answered that it has been a longer project than planned. MARKSANS is planning to file couple of DMFs in the mid of 2023 where there is captive consumption and growth is by strength.<\/li>\n<\/ul>\n<ul>\n<li>[00:32:28] Agastya Dave from CAO Capital asked about any progress on the acquisition in the front end in the EU markets. Mark Saldanha MD replied that it is still pursuing that part and plans to expand in its geographies. MARKSANS is also exploring different M&amp;As and have been in active dialogs for last 6 months.<\/li>\n<\/ul>\n<ul>\n<li>[00:35:07] Manuj Mathew enquired if the buyback is over. Mark Saldanha MD said the company has completed about 50% plus of the buyback, but it\u2019s not over.<\/li>\n<\/ul>\n<ul>\n<li>[00:38:19] Manuj Mathew asked that as of today\u2019s capacity what volume is expected from Teva. Mark Saldanha MD answered that from April, the Teva capacity is not very large, about 1.5 billion tablets, and about INR200 crores per quarter can be achieved once the objective of increasing capacity is met.<\/li>\n<\/ul>\n<ul>\n<li>[00:44:50] Utsav of DAM Capital asked about the company\u2019s plans in the Australia and RoW markets. Mark Saldanha MD said Australia was challenging in terms of pricing pressure but MARKSANS expects this market to grow and it has evolved. In RoW, the company expects to double its revenue in next couple of years.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Marksans Pharma Limited (MARKSANS) Q2 FY23 Earnings Concall Q&amp;A Highlights: [00:12:45] Madhav Shastri asked about the new acquisition made of Teva Pharma, and the expected capex on the facility. Mark Saldanha MD clarified that the amount the company plans to spend including the acquisition cost and capex is INR200 crore. [00:13:36] Madhav [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Marksans Pharma Limited Q2 FY23 Earnings Conference Call Insights #MARKSANS #Q2 #FY23 #Earnings #Stocks","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[10169,1115],"class_list":["post-138022","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":133596,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-limited-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":138022,"position":0},"title":"Marksans Pharma Limited Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 30, 2022","format":false,"excerpt":"https:\/\/youtu.be\/9PAJ7vTTG5E Key highlights from Marksans Pharma Limited (MARKSANS) Q1 FY23 Earnings Concall Management Update: MARKSANS said it aims to increase its R&D spend to 4-5% of sales over the coming years. The company also plans to expand its capacities over the next 12-18 months which would help expand margins in\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":141872,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-limited-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":138022,"position":1},"title":"Marksans Pharma Limited Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"February 15, 2023","format":false,"excerpt":"Key highlights from Marksans Pharma Limited (MARKSANS) Q3 FY23 Earnings Concall Q&A Highlights: [00:08:54] Riddhesh Gandhi from Discovery Capital asked why there is revenue growth despite high single-digit price decreases. Mark Saldanha MD said pricing pressure and price erosion continues in all functional countries, mainly in the US. This is\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":130765,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-limited-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":138022,"position":2},"title":"Marksans Pharma Limited Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"June 23, 2022","format":false,"excerpt":"Key highlights from Marksans Pharma Limited (MARKSANS) Q4 FY22 Earnings Concall \u00a0 Q&A Highlights: Vijay Nahar - Individual Investor - Analyst Challenges affecting cost and what costs were passed on to the consumers? Mark Saldanha - Managing Director The challenge was China lockdown. Had cascading impact on all input cost\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":156124,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-limited-q2-fy24-earnings-conference-call-insights\/","url_meta":{"origin":138022,"position":3},"title":"Marksans Pharma Limited Q2 FY24 Earnings Conference Call Insights","author":"Praveen","date":"November 13, 2023","format":false,"excerpt":"Key highlights from Marksans Pharma Limited (MARKSANS) Q2 FY24 Earnings Concall Financial Performance Revenues grew 17% year-on-year to INR531 crores in Q2 FY'24. EBITDA up 41.9% year-on-year to INR113.9 crores in Q2. PAT grew 39.5% to INR83.9 crores in Q2. Gross margin improved 174 bps to 52.4% in Q2. For\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":130453,"url":"https:\/\/alphastreet.com\/india\/glenmark-pharmaceuticals-limited-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":138022,"position":4},"title":"Glenmark Pharmaceuticals Limited Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"June 2, 2022","format":false,"excerpt":"https:\/\/youtu.be\/uTUQ9VpSoiU Key highlights from Glenmark Pharmaceuticals Limited (GLENMARK) Q4 FY22 Earnings Concall Management Update: GLENMARK said the India business continues to significantly outperform industry growth rates, continuing the trend of the past several years. The company said it filed a total of 19 ANDA applications with the U.S. FDA in\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":175548,"url":"https:\/\/alphastreet.com\/india\/marksans-pharma-limited-marksans-q2-2025-earnings-call-transcript\/","url_meta":{"origin":138022,"position":5},"title":"Marksans Pharma Limited (MARKSANS) Q2 2025 Earnings Call Transcript","author":"News desk","date":"January 22, 2026","format":false,"excerpt":"Marksans Pharma Limited (NSE: MARKSANS) Q2 2025 Earnings Call dated Nov. 13, 2024 Corporate Participants: Mark Saldanha \u2014 Chairman & Managing Director Jitendra Sharma \u2014 Group Chief Financial Officer Analysts: Kashish Thakur \u2014 Analyst Ishita Jain \u2014 Analyst Unidentified Participant Aditya Pal \u2014 Analyst Dipesh Sanchit \u2014 Analyst Runit Kapoor\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/138022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=138022"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/138022\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=138022"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=138022"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=138022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}